• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Carboxylic acid derivatives Carboxylic acid amides

Recent Advances in the Study of 5-Carbamoyl-1H-imidazole-4-carboxylic acid (CAS: 773108-85-3)

5-Carbamoyl-1H-imidazole-4-carboxylic acid (CAS: 773108-85-3) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of nucleoside analogs and enzyme inhibitors. Recent studies have highlighted its significance in medicinal chemistry, with applications ranging from antiviral therapies to cancer treatment. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

One of the most notable advancements in the study of 5-Carbamoyl-1H-imidazole-4-carboxylic acid is its role in the synthesis of novel nucleoside analogs. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound serves as a versatile building block for the development of purine-based antiviral agents. Researchers successfully utilized 773108-85-3 to create a series of modified nucleosides with enhanced activity against RNA viruses, including SARS-CoV-2 variants. The study reported a 40% improvement in viral inhibition compared to traditional nucleoside analogs, suggesting its potential as a lead compound for future antiviral drug development.

In the field of oncology, recent investigations have explored the enzyme inhibitory properties of derivatives synthesized from 5-Carbamoyl-1H-imidazole-4-carboxylic acid. A preclinical study published in Bioorganic & Medicinal Chemistry Letters (2024) identified several potent inhibitors of phosphoinositide 3-kinase (PI3K), a key signaling pathway in cancer cell proliferation. The lead compound, derived from 773108-85-3, showed selective inhibition of PI3Kα with an IC50 of 12 nM, along with promising antitumor activity in xenograft models of breast cancer. These findings underscore the compound's potential as a scaffold for developing targeted cancer therapies.

The synthetic accessibility of 5-Carbamoyl-1H-imidazole-4-carboxylic acid has also been a focus of recent research. A 2024 paper in Organic Process Research & Development described an improved, scalable synthesis route for 773108-85-3 that reduces production costs by 35% while maintaining high purity (>99.5%). This advancement addresses previous challenges in large-scale production, making the compound more accessible for pharmaceutical development. The new synthetic approach utilizes a biocatalytic step, aligning with the growing trend toward green chemistry in drug manufacturing.

Emerging research has also investigated the compound's potential in treating metabolic disorders. A recent study in the European Journal of Medicinal Chemistry (2024) reported that structural analogs of 5-Carbamoyl-1H-imidazole-4-carboxylic acid exhibit significant activity as AMP-activated protein kinase (AMPK) activators. These compounds demonstrated promising effects in improving glucose uptake and lipid metabolism in diabetic animal models, suggesting potential applications in type 2 diabetes and obesity treatment. The lead candidate showed 70% higher bioavailability than existing AMPK activators in preclinical testing.

In conclusion, recent studies on 5-Carbamoyl-1H-imidazole-4-carboxylic acid (773108-85-3) have expanded our understanding of its versatility in medicinal chemistry. From its role in nucleoside analog synthesis to its applications in cancer and metabolic disease treatment, this compound continues to offer valuable opportunities for drug discovery. The development of more efficient synthetic routes and the identification of novel biological activities position 773108-85-3 as an important building block for future pharmaceutical research. Further investigation into its structure-activity relationships and mechanism of action will likely yield additional therapeutic candidates in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)